Adagio Therapeutics $356 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Experience
To find Davis Polk deals and cases of particular interest, select filters based on practice, industry, region, lawyer and keyword.
Filters
RxSight $117.6 million IPO
We advised the underwriters in connection with the IPO and Nasdaq listing
Tenaya Therapeutics $207 million IPO
We advised the underwriters on the IPO and Nasdaq listing
SOPHiA GENETICS $234 million IPO and $20 million private placement
We advised SOPHiA GENETICS on its IPO, Nasdaq listing and concurrent private placement
TScan Therapeutics $100 million IPO
We advised the underwriters on the IPO and Nasdaq listing
Sight Sciences $276 million IPO
We advised the underwriters in connection with the IPO and Nasdaq listing
Novo Nordisk acquisition of Neotope Neuroscience
We advised Novo Nordisk on the acquisition
Novo Holdings investment in Availity
We advised Availity on the investment
GH Research $184 million IPO
We advised GH Research on the IPO and Nasdaq Listing
ATAI Life Sciences $258.8 million IPO
We advised the underwriters on the IPO and Nasdaq listing